August 1, 2016 09:51 AM EDT
News Briefing

Pro­to­cols: Pri­vate eq­ui­ty buy-in val­ues in­Ven­tiv at $3.8B; Cel­gene de­nies char­i­ty scheme al­le­ga­tions

John Carroll

Editor & Founder

The CRO in­Ven­tiv Health has bagged a buy-in from Ad­vent Health that val­ues the com­pa­ny at $3.8 bil­lion. Ad­vent now be­comes a co-own­er of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times